US to invest $472 million more in Moderna to speed up vaccine process

Moderna has unveiled a modification to its contract with the BARDA for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3...

Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Pivotal Phase Global Study

Pfizer & BioNTech SE announced the start of a global Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside modified messenger RNA candidate from their BNT162 mRNA...

Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin

Sterling Pharma Solutions has signed an agreement with Moleculin Biotech, Inc., to support the company's expanded development efforts for its potential COVID-19 treatment, WP1122....

FUJIFILM Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization for biologics, viral vaccines and gene therapies, announced that its College Station, Texas...

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership

Thermo Fisher Scientific and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients.

Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Sanofi and GSK have reached an agreement, subject to final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine.

FDA Grants Emergency Use Authorization for Eli Lilly, Sandia National Labs Coronavirus PCR Tests

The US FDA granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Eli Lilly and Sandia National...

Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19

Cipla Limited announced that it has been granted regulatory approval by the DCGI for the launch of Favipiravir in the country under the brand name Ciplenza.

Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19

Glenmark Pharmaceuticals announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients conducted across seven clinical sites in India. ...

Optimus Pharma gets nod from DGCI to make COVID-19 drug 'Favicovid'

Optimus Pharma said it has received the Drugs Controller General of India approval to manufacture and market Favipiravir 200 mg tablets for the treatment of patients with mild to moderate COVID-19....

Dalton Pharma Services Partners with Vido-InterVac to Combat Covid-19

Dalton Pharma Services is pleased to announce a partnership with the University of Saskatchewan’s Vaccine & Infectious Disease Organization International Vaccine Centre, a global leader...

AstraZeneca's Calquence Receives Positive CHMP Opinion For Chronic Blood Cancer

AstraZeneca's Calquence has been recommended for marketing authorisation in the EU for the treatment of adult patients with chronic lymphocytic leukaemia, the most common type of leukaemia in adults....

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene related peptide receptor antagonist met its primary endpoint...

CPhI Japan rescheduled for Spring 2021 with digital solutions to be launched

CPhI Japan organised by Informa announces that, following a detailed review with partners and key industry stakeholders and to ensure the health and safety of our community, the event will be postponed until *April 14-16, 2021.....